<DOC>
	<DOC>NCT00235911</DOC>
	<brief_summary>The primary objective is to compare the effects of Symbicort SiT and treatment according to NHG-guidelines on bronchial hyperresponsiveness in asthmatic patients, as measured by PD20 histamine, and to validate the Bronchial Hyperresponsiveness Questionnaire (BHQ).</brief_summary>
	<brief_title>Symbicort Single Inhaler Therapy for Asthma in a General Practice Setting</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>diagnosis of mild to moderate asthma, FEV1 ³ 60% of predicted normal values prebronchodilator, daily use of inhaled GCS during the last 3 months Regular need of &gt;4 inhalations of a shortacting b2agonist/day, known or suspected hypersensitivity to any of the investigational drugs or inhaled lactose, use of any bblocking agent, having smoked ³10 packyears</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>